

ZETA opens location in Singapore: New service offering for the Asian market

ZETA has established itself internationally as a one-stop-shop for the biopharmaceutical industry. With ZETA's opening of its new subsidiary in Singapore, Asian companies in the pharmaceutical and biotech industries can now also benefit from customer-specific services on-site.

Risk and complexity management in manufacturing biopharmaceutical products are central challenges confronting companies in this industry. As an engineering specialist for biopharmaceutical process plants, ZETA reduces interfaces in a targeted manner, enabling a significant reduction in project lead times. This is an innovative approach from which Asian companies can now also benefit from the new Singapore subsidiary.

Comprehensive engineering know-how for the pharmaceutical and biotech industries

ZETA's services are not only valued by long-term partners in Europe. Big pharma on the international market also rely on the extensive expertise of ZETA experts. ZETA supports customers along the entire drug development and manufacturing process with sophisticated solutions from the laboratory to industrial production.

"We see ourselves as a one-stop-shop that, in addition to planning, design, development, manufacturing, automation, digitization, and maintenance of customer-specific aseptic process solutions, also combines the planning of HVAC and cleanroom technology under one roof. We are actively contributing to the rapid market launch and market supply of life-saving active ingredients through this integrated approach," emphasizes Andreas Marchler, Managing Director of the ZETA Group.

Customized services for Asia

With its new subsidiary in Singapore, ZETA intensifies its business activities in Asia. "The biopharmaceutical market in Asia is growing rapidly. Singapore, with its talent pool, infrastructure, and regional connectivity, is the natural choice for ZETA to establish a team of highly competent engineers capable of meeting our customer needs," emphasizes Sushaant Bakhru, Managing Director of ZETA Singapore.

In recent years, numerous projects have been implemented with Asian customers, such as the planning, construction, and automation of a USP production plant expansion in South Korea or DSP-Systems in Singapore. The Singapore branch will now ensure even greater cooperation with these customers: "The Singapore office marks an important step for ZETA's presence in the region, positioning us as a truly global player in the industry. Being closer to customers will allow us to be flexible and agile in responding to their requests," Bakhru points out.

About

The ZETA Group, with 1000 highly qualified employees and 17 subsidiaries worldwide, specializes in planning, automation, digitalization and maintenance of customized biopharmaceutical facilities for aseptic process solutions. ZETA acts as a one-stop-shop, combining plant engineering with HVAC and cleanroom design.

Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines, and infusions, are produced in these highly complex, "tailor-made" facilities. ZETA supports its customers along the entire drug development and manufacturing pathway with sophisticated solutions from the laboratory to industrial-scale production. ZETA maintains an in-house technical center (ZETA TechCenter), in which innovative developments are driven forward in close collaboration with customers from the biopharmaceutical industry.

ZETA is actively taking steps towards a more sustainable future for the industry as a whole. Through ZETA's decarbonization strategies, emissions are specifically reduced during the biopharmaceutical manufacturing process.

Contact

Andreas Marchler

Managing Director ZETA Group
+43 (3136) 9010 1002
+43 (664) 808 528 1002
andreas.marchler@zeta.com

Sushaant Bakhru

Managing Director ZETA SG. Pte. Ltd.
German Centre for Industry and Trade Pte. Ltd.
25 International Business Park Rd
609916 Singapore
+43 (664) 808 52 1408
sushaant.bakhru@zeta.com

Photographic material

Reprint with ZETA copyright notice free of charge



Andreas Marchler emphasizes that collaboration with ZETA will lead to a faster market launch of biopharmaceutical active ingredients.



Sushaant Bakhru supports Asian pharmaceutical and biotech companies on-site as a competent CEO and industry leader.